Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06170229
Other study ID # PT-2023-DK-3
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date February 23, 2024
Est. completion date December 31, 2026

Study information

Verified date February 2024
Source Frederiksberg University Hospital
Contact Marius Henriksen, PhD
Phone +4538164160
Email marius.henriksen@regionh.dk
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study aims to compare the effects of an education and High Intensity Interval Training program (eHIIT) with the widely used Neuromuscular Exercise and education program (NEMEX-e) on knee OA symptoms and risk factors for cardiovascular disease in people with knee OA and at least one risk factor for developement of cardiovascular disease. The main research questions the study aims to answer are: - Is the eHIIT program better than the NEMEX-e program for reducing the risk of cardiovascular disease? - Are the two programs equally good at providing improvement in knee symptoms?


Recruitment information / eligibility

Status Recruiting
Enrollment 150
Est. completion date December 31, 2026
Est. primary completion date June 30, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age =18- years - Diagnosis of tibiofemoral knee OA according to the American College of Rheumatology criteria - Radiographically confirmed diagnosis of tibiofemoral OA based on radiographs not older than 6 months. - Average knee pain level = 4 (0=No pain and 10=Worst pain) over the past week (7 days) - At least one of following risk factors for development of cardiovascular disease: - Body mass index = 30 kg/m2 - Hypertension (or in treatment of): Systolic = 135 and/or diastolic = 85 mm Hg - Elevated HbA1c (or in treatment of): = 130.7 mg/dL (44 mmol/mol) - Elevated Triglycerides (or in treatment of): = 150 mg/dL (1.7 mmol/L) - Elevated Cholesterol (or in treatment of) (Low density lipides, LDL): LDL = 54 mg/dL (3.0 mmol/L) Exclusion Criteria: - Contraindication to exercise (e.g., resting systolic blood pressure > 200 or diastolic blood pressure > 115, acute or reoccurring chest pain) - Unstable body weight the last 3 months (gain/loss outside +/- 5 kg) - Planned weight loss (non-pharmacological, pharmacological, and surgical) during study participation - Known current cancer - Major cardiovascular event within the last 5 years - Insulin dependent type 1 or type 2 diabetes - Psoriatic, rheumatoid, or gouty arthritis disease - Generalized pain syndromes such as fibromyalgia - Lumbar or cervical nerve root compression syndromes - Scheduled surgery during study participation - Treatment with biological medication - Impairments that prevent performance in high intensity aerobic exercise - Current or planned participation in other health research intervention studies - Pregnant/considering pregnancy - Any other condition or impairment that, in the opinion of the investigator, makes a potential participant unsuitable for participation or which obstruct participation, such as a large knee joint effusion, uncontrolled diabetes/hypertension, psychiatric or cognitive disorders, language barriers, or opiate dependency.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
eHIIT
Education and High intensity Interval Training (Aerobic Exercise) The focus of the one educational session is rationale for aerobic exercise, expected physiological effects of aerobic exercise, diet when performing an exercise program, how the knee accommodates to exercise (including potential experience of muscle soreness and how that is different from joint pain), and management of potential knee OA symptom flares. HIIT is an aerobic exercise form. The eHITT protocol consist of eight 2-minute intervals of high intensity training (with the goal to train at a heart rate of at least 80% of HRmax) followed by 2 minutes of moderate training intensity (with the goal to train at a heart rate of at least 60% of HRmax). There will be several types of exercise modalities for aerobic exercise available (treadmills, cross-trainers, row- and cycle ergometers) and participants may choose whichever they prefer.
NEMEX-e
Education and Neuromuscular Exercise The focus of the two educational sessions is on providing knowledge of OA and treatment options to the participants, with a special focus on knee OA, diet, and exercise and its benefits. Furthermore, advice about self-management is given. The exercises are based on neuromuscular principles to improve sensorimotor control and achieve compensatory functional stability. Sensorimotor control is the ability to coordinate muscle activity and maintain functional stability during movement allowing for joint stability during physical activity. Various positions (sitting, lying, standing) are used to achieve the desired postural activity. The overall goal is to obtain muscle control and stability in situations resembling daily life and/or more strenuous activities. The focus is on achieving good quality of the performance in each exercise with appropriate postural orientation (e.g., joint positioned appropriately in relation to each other).

Locations

Country Name City State
Denmark The Parker Institute, Frederiksberg Hospital Copenhagen

Sponsors (1)

Lead Sponsor Collaborator
Frederiksberg University Hospital

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Other Knee-related Quality of Life The Knee injury and Osteoarthritis Outcome Score (KOOS) quality of life subscale (KOOS-QoL), a disease-specific patient-reported instrument designed to assess knee-related quality of life in patients with knee osteoarthritis.
The KOOS-QoL subscale is scored on a 0-100 scale with 100 indicating best possible knee-related quality of life and 0 indicating worst possible knee-related quality of life.
Baseline, week 8, week 12 and week 26
Other Knee Symptoms The Knee injury and Osteoarthritis Outcome Score (KOOS) symptoms subscale (KOOS-symptoms), a disease-specific patient-reported instrument designed to knee symptoms in patients with knee osteoarthritis.
KOOS-symptom is scored on a 0-100 scale with indicating no symptoms and 0 indicating worst possible symptoms.
Baseline, week 8, week 12 and week 26
Other Knee Function in Sports and Recreational activities The Knee injury and Osteoarthritis Outcome Score (KOOS) Sports and Recreation subscale (KOOS-Sports/Recreation), a disease-specific patient-reported instrument designed to knee symptoms in patients with knee osteoarthritis.
KOOS-Sports/Recreation is scored on a 0-100 scale with indicating no symptoms and 0 indicating worst possible symptoms.
Baseline, week 8, week 12 and week 26
Other The World Health Organisation - Five Well-Being Index (WHO-5) Patient reported mental well-being will be obtained with the The World Health Organisation 5-Well-Being Index consisting of five questions each scored on a 0 to 5 scale.
Raw score: 0 represents worst possible well-being and 25 represents best possible well-being.
Percentage score: 0 represents worst possible well-being and 100 represents best possible well-being.
Baseline, week 8, week 12 and week 26
Other OMERACT-OARSI treatment responder criteria A classification of patients as a positive responder based on the Outcome Measures in Rheumatology (OMERACT) and Osteoarthritis Research Society International (OARSI) (OMERACT-OARSI) responder criteria that classifies patients according to improvements in pain (co-primary outcome),function (secondary outcome) and patient global assessment (secondary outcome).
Each participant is classified as either a "responder" or a "non-responder" at each of the post-baseline follow-ups.
Baseline, week 8, week 12 and week 26
Other Sleep quality using the global Single-item sleep quality scale (SQS) Sleep quality will be obtained with the global Single-item sleep quality scale (SQS). SQS is scored on 0-10 scale with 0 representing worst possible sleep quality and 10 representing best possible sleep quality. Baseline, week 8, week 12 and week 26
Other Nightly pain Self-reported pain during the night is obtained on a 0-2 scale with 0=No nightly pain, 1=pain at movement or in certain positions, and 2=Pain even without movement. Baseline, week 8, week 12 and week 26
Other Maximal aerobic capacity (VO2 peak) during a cardiopulmonary exercise test A cardiopulmonary exercise test will be used to assess maximal aerobic capacity (VO2peak) measured in ml/min/kg. Baseline, week 8, week 12 and week 26
Other Maximum work during a cardiopulmonary exercise test The maximal work during the cardiopulmonary exercise test measured in Watts (W) Baseline, week 8, week 12 and week 26
Other Respiratory exchange ratio (RER) during a cardiopulmonary exercise test The respiratory exchange ratio (RER) during the cardiopulmonary exercise test is calculated as the ratio of carbon-dioxide production (VCO2) and oxygen consumption (VO2) Baseline, week 8, week 12 and week 26
Other Maximal hear rate during a cardiopulmonary exercise test The maximal heart rate during a cardiopulmonary exercise test is recorded as beats/min. Baseline, week 8, week 12 and week 26
Other Lean body mass from a dual x-ray absorptiometry scan Dual x-ray absorptiometry (DXA) will be used to assess lean body mass Baseline, Week 12 and Week 26
Other Total fat mass from a dual x-ray absorptiometry scan Dual x-ray absorptiometry (DXA) will be used to assess total fat mass. Baseline, Week 12 and Week 26
Other Bone mineral density from a dual x-ray absorptiometry scan Dual x-ray absorptiometry (DXA) will be used to assess bone density. Baseline, Week 12 and Week 26
Other Hip and waist circumstance The measurements are recorded in cm and measured during a clinical examination using a measurement tape and standardized procedures Baseline, Week 12 and Week 26
Other Leg extensor power Muscle power (force × velocity) of the lower limb of the target knee will be assessed using the Nottingham power rig. In a seated position, the participants will be instructed to push with a single leg against a plate at maximal effort/force. Baseline, Week 12 and Week 26
Other Analgesics usage The participants' use of over-the-counter paracetamol and ibuprofen will be recorded during an interview with an investigator. Baseline, Week 12 and Week 26
Other Pressure pain sensitivity A hand-held pressure algometer will used to assess pressure pain thresholds (PPTs). Pressure will be applied at a rate of approximately 30 kilopascal per second (kPa/s), with a 1 cm2 probe. All participants are instructed to push a button when they feel that the pressure becomes just barely painful. PPTs from the medial tibiofemoral joint space on the target knee and the contralateral elbow will be assessed Baseline, Week 12 and Week 26
Other C-reactive protein concentration From a blood sample Baseline, Week 12 and Week 26
Other Interleukin 6 (IL6) concentration From a blood sample Baseline, Week 12 and Week 26
Primary Maximal oxygen consumption (VO2max) Cardiopulmonary exercise test (CPET) on an ergometer bicycle for evaluation maximal oxygen consumption (VO2max) measured in ml/min/kg Baseline and Week 12
Primary Knee pain The Knee injury and Osteoarthritis Outcome Score (KOOS) pain subscale (KOOS-pain), a disease-specific patient-reported instrument designed to assess knee pain in patients with knee osteoarthritis.
The KOOS-pain subscale is scored on a 0-100 scale with 100 indicating no pain and 0 indicating extreme pain.
Baseline and Week 12
Secondary Maximal oxygen consumption (VO2max) Cardiopulmonary exercise test (CPET) on an ergometer bicycle for evaluation maximal oxygen consumption (VO2max) measured in ml/min/kg Week 8 and week 26
Secondary Knee pain The Knee injury and Osteoarthritis Outcome Score (KOOS) pain subscale (KOOS-pain), a disease-specific patient-reported instrument designed to assess knee pain in patients with knee osteoarthritis.
The KOOS-pain subscale is scored on a 0-100 scale with 100 indicating no pain and 0 indicating extreme pain.
Week 8 and week 26
Secondary Body Mass Body mass measured in kilograms using a scale Baseline, Week 12 and Week 26
Secondary Blood Pressure Systolic and Diastolic blood pressure Baseline, Week 12 and Week 26
Secondary Triglyceride concentration From a blood sample Baseline, Week 12 and Week 26
Secondary Low Density Lipids (LDL) concentration From a blood sample Baseline, Week 12 and Week 26
Secondary Cholesterol concentration From a blood sample Baseline, Week 12 and Week 26
Secondary Glucose concentration From a blood sample Baseline, Week 12 and Week 26
Secondary HbA1c concentration From a blood sample Baseline, Week 12 and Week 26
Secondary Patient Global Assessment of disease Impact Patient-reported degree of patient's perceived impact of their knee OA on their overall life will be obtained using a 100 mm analogue scale (VAS) with anchors: 0=" No impact" and 100 = "Worst imaginable impact". Baseline, week 8, week 12 and week 26
Secondary Physical Functioning The Knee injury and Osteoarthritis Outcome Score (KOOS) function subscale (KOOS-function), a disease-specific patient-reported instrument designed to assess physical functioning in patients with knee osteoarthritis.
The KOOS-function subscale is scored on a 0-100 scale with 100 indicating no functional impairments and 0 indicating extreme functional impairments.
Baseline, week 8, week 12 and week 26
Secondary Health related quality of Life and physical and mental well-being (Short Form 12 (SF-12)) The 12-item short form health questionnaire (SF-12) is a measure of physical and mental health.
The physical health component is scored between 0-72. The mental health component is scored between 0-70. For both components 0 mean a worse outcome.
Baseline, week 8, week 12 and week 26
See also
  Status Clinical Trial Phase
Recruiting NCT04651673 - Prescribed Knee Brace Treatments for Osteoarthritis of the Knee (Knee OA)
Completed NCT05677399 - Knee Osteoarthritis Treatment With Peloidotherapy and Aquatic Exercise. N/A
Active, not recruiting NCT04043819 - Evaluation of Safety and Exploratory Efficacy of an Autologous Adipose-derived Cell Therapy Product for Treatment of Single Knee Osteoarthritis Phase 1
Recruiting NCT06000410 - A Study to Evaluate the Efficacy of Amniotic Suspension Allograft in Patients With Osteoarthritis of the Knee Phase 3
Completed NCT05014542 - Needling Techniques for Knee Osteoarthritis N/A
Recruiting NCT05892133 - Prehabilitation Effect on Function and Patient Satisfaction Following Total Knee Arthroplasty N/A
Recruiting NCT05528965 - Parallel Versus Perpendicular Technique for Genicular Radiofrequency N/A
Active, not recruiting NCT03472300 - Prevalence of Self-disclosed Knee Trouble and Use of Treatments Among Elderly Individuals
Active, not recruiting NCT02003976 - A Randomized Trial Comparing High Tibial Osteotomy Plus Non-Surgical Treatment and Non-Surgical Treatment Alone N/A
Active, not recruiting NCT04017533 - Stability of Uncemented Medially Stabilized TKA N/A
Completed NCT04779164 - The Relation Between Abdominal Obesity, Type 2 Diabetes Mellitus and Knee Osteoarthritis N/A
Recruiting NCT04006314 - Platelet Rich Plasma and Neural Prolotherapy Injections in Treating Knee Osteoarthritis N/A
Recruiting NCT05423587 - Genicular Artery Embolisation for Knee Osteoarthritis II N/A
Enrolling by invitation NCT04145401 - Post Market Clinical Follow-Up Study- EVOLUTION® Revision CCK
Active, not recruiting NCT03781843 - Effects of Genicular Nerve Block in Knee Osteoarthritis N/A
Completed NCT05974501 - Pre vs Post Block in Total Knee Arthroplasty (TKA) Phase 4
Completed NCT05324163 - Evaluate Efficacy and Safety of X0002 in Treatment of Knee Osteoarthritis Phase 3
Completed NCT05529914 - Effects of Myofascial Release and Neuromuscular Training for Pes Anserine Syndrome Associated With Knee Osteoarthritis N/A
Recruiting NCT05693493 - Can Proprioceptive Knee Brace Improve Functional Outcome Following TKA? N/A
Not yet recruiting NCT05510648 - Evaluation of the Effect of High-intensity Laser Therapy in Knee Osteoarthritis N/A